Patent estate
BRACCO — Patent Portfolio
1 drug with active patents · 3 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Sincalide (SINCALIDE)
Cliff 2038 · 12yMethod of Use 3
-
US11110063
Vuln 70
2038-04-20
This patent protects storage stable formulations of sincalide, including solid and liquid compositions, and methods for making and administering them.
-
US11318100
Vuln 70
2038-04-20
This patent protects storage stable formulations of sincalide, including solid and liquid compositions, and methods for making and administering them.
-
US11737983
Vuln 70
2038-04-20
This patent protects storage stable formulations of sincalide, including solid and liquid compositions, and methods for making and administering them.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 3 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track BRACCO's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export